Human Immunodeficiency Virus (HIV) Infection Clinical Trial
Official title:
A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Participants With HIV-1, Who Are 4 Weeks to Less Than 12 Years of Age and Weigh Less Than 45 kg
This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to <12 years and weighing <45 kg, who are treatment-naive (TN) or have been virologically suppressed (VS) on stable combination antiretroviral therapy (cART) for ≥3 months with no history of treatment failure. The first primary objective is to evaluate the steady state pharmacokinetics (PK) of doravirine (DOR) [MK-1439] when given in combination with 2 nucleoside/nucleotide analog reverse transcriptase inhibitors (NRTIs) or as part of the fixed dose combination (FDC) of DOR/lamivudine (3TC)/tenofovir disproxil fumarate (TDF) in participants ≥6 to <12 years and weighing ≥14 to <45 kg. The second primary objective is to evaluate the safety and tolerability of DOR when given with 2 NRTIs or as part of the FDC of DOR/3TC/TDF, in participants ≥6 to 12 years and weighing ≥14 to <45 kg, through Week 24.
Participants who complete the Week 96 visit will be eligible to enroll in an Extension Study in which they may continue to receive DOR until it is commercially available, or for up to an additional 224 weeks (whichever comes first). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02715700 -
Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)
|
Phase 1 | |
| Completed |
NCT03667547 -
Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)
|
Phase 4 | |
| Completed |
NCT01422330 -
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
|
Phase 4 | |
| Active, not recruiting |
NCT05452616 -
Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of Tuberculosis
|
N/A | |
| Completed |
NCT04515641 -
Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)
|
Phase 1 | |
| Not yet recruiting |
NCT06430905 -
Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART
|
Phase 1 | |
| Terminated |
NCT02818283 -
Soy Modulation of Immune Activation, LDL- Levels, and Lowering Inflammation by Pretzel Isoflavone Dietary Intervention
|
N/A | |
| Completed |
NCT04303156 -
Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)
|
Phase 1 | |
| Completed |
NCT00717067 -
Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
|
Phase 4 | |
| Completed |
NCT00821535 -
Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers
|
Phase 1 | |
| Completed |
NCT03618511 -
Interventions to Improve HIV Antiretroviral Therapy Adherence
|
N/A | |
| Completed |
NCT01768182 -
Folinic Acid and Vascular Reactivity in HIV
|
N/A |